Journal article : Review
Exploiting azide-alkyne click chemistry in the synthesis, tracking and targeting of platinum anticancer complexes.
- Abstract:
- Click chemistry is fundamentally important to medicinal chemistry and chemical biology. It represents a powerful and versatile tool, which can be exploited to develop novel Pt-based anticancer drugs and to better understand the biological effects of Pt-based anticancer drugs at a cellular level. Innovative azide–alkyne cycloaddition–based approaches are being used to functionalise Pt-based complexes with biomolecules to enhance tumour targeting. Valuable information in relation to the mechanisms of action and resistance of Pt-based drugs is also being revealed through click-based detection, isolation and tracking of Pt drug surrogates in biological and cellular environments. Although less well-explored, inorganic Pt-click reactions enable synthesis of novel (potentially multimetallic) Pt complexes and provide plausible routes to introduce functional groups and monitoring Pt-azido drug localisation.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.7MB, Terms of use)
-
- Publisher copy:
- 10.1016/j.cbpa.2019.12.001
Authors
- Publisher:
- Elsevier
- Journal:
- Current Opinion in Chemical Biology More from this journal
- Volume:
- 55
- Pages:
- 59-68
- Publication date:
- 2020-01-13
- Acceptance date:
- 2019-12-02
- DOI:
- EISSN:
-
1879-0402
- ISSN:
-
1367-5931
- Pmid:
-
31945705
- Language:
-
English
- Keywords:
- Subtype:
-
Review
- Pubs id:
-
1083899
- Local pid:
-
pubs:1083899
- Deposit date:
-
2020-07-21
- ARK identifier:
Terms of use
- Copyright holder:
- Farrer and Griffith
- Copyright date:
- 2020
- Rights statement:
- © 2019 The Author(s). Published by Elsevier Ltd. This is anopen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record